Clinical Trials - March 10, 2020
Clinical trials in Norway affected by the COVID-19 outbreak
As a precautionary measure, in the continuous efforts to limit the spreading of the COVID-19 outbreak, and to shelter patients as well as healthcare staff, external personnel are given restricted access to hospitals, which consequently affects monitoring, auditing and inspections of ongoing clinical trials. This was reported in a press release from Legemiddelindustrien (LMI) and […]
Pharma article - January 6, 2020
PCI Biotech – On the cusp of a revolution in cancer treatments
While selecting a cancer treatment can be challenging, delivering it can be even more challenging. Not all molecules are readily absorbed by a cell and finding a way to plant treatments into the cell’s body can increase their effectiveness. That is where photochemical internalization (PCI) technology, an intracellular delivery method, comes in. Norwegian biopharmaceutical company […]
In a new job - December 19, 2019
Namir Hassan is the new CEO of Zelluna Immunotherapy
Zelluna Immunotherapy has announced the appointment of Namir Hassan as its chief executive officer (CEO). “At this stage of Zelluna’s evolution, we are delighted to appoint Namir Hassan as CEO. Namir has made an invaluable contribution to Zelluna since he joined the company in 2018 as chief scientific officer (CSO). He has a strong scientific […]
In a new job - November 9, 2019
Zelluna Immunotherapy appoints a new member of its board
Zelluna Immunotherapy has announced the appointment of Bent Jakobsen to its board. “Zelluna is now preparing to enter its first TCR based cell therapy into the clinic to evaluate its potential to treat cancer patients worldwide. After appointing an experienced senior management team, Zelluna has also decided to further strengthen our board with deep international […]
Clinical Trials - November 6, 2019
Vaccibody announces positive clinical trial results
Vaccibody has announced strong preliminary data from the ongoing VB N-01 phase I/IIa clinical trial of the VB10.NEO neoantigen cancer vaccine. The data is from the first 16 patients assessed for safety after treatment with a VB10.NEO, and the first 14 patients assessed for clinical responses. Key highlights include: • Clinical responses were observed after […]
Past events - September 25, 2019
Norway for Life Science at NLSDays 2019
The biggest key players from the life science industry in Norway came together in Malmö with a common goal: to promote Norwegian life science and build Nordic collaboration. Sofia Lindén, Communications adviser at Oslo Cancer Cluster, has summarized the NLSDays 2019 and the Norwegian participation. The life science industry in Norway is booming and collaboration […]
